[Tiracizine in the treatment of ventricular arrhythmia (preliminary study)].
Tiracizine a new antiarrhythmic drug class Ia was tested in a open crossover study in a group of 46 patients with more than 2500 ventricular extrasystoles per 24 hours or with ventricular arrhythmias III or a higher Lown class. The authors revealed a statistically significant drop of ventricular extrasystoles and a significant reduction of arrhythmias class IV of Lown's classification with a general shift of arrhythmias to lower classes. Improvement by at least one class occurred in 63%, deterioration without clinical impact in 11%. The drug does not have a clinical effect on haemodynamics. Side-effects of an anticholinergic type were recorded in 13% and a toxic allergic exanthema was observed in 6.5%. Tiracizine extends the spectrum of membrane antiarrhythmic drugs. Its effectiveness is similar as that of propafenon.
Stejfa
M
M
I. interní klinika FN u sv. Anny v Brnĕ.
Zeman
K
K
Groch
L
L
Bytesník
J
J
Krausová
R
R
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D003984:Dibenzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000009:adverse effects / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines; D011405:Propafenone; C048166:tiracizine
Tiracizin v lécbĕ komorových arytmií (predbĕzná studie).